

**For Release Date  
March 6, 2020**

## **BlueStone Portfolio Company, Paradigm Diagnostics, Sold to Exact Sciences**

**Tucson, Arizona. March 6, 2020** – BlueStone Venture Partners announces the acquisition of one of its portfolio companies, Paradigm Diagnostics, Inc (“Paradigm”) by Exact Sciences Corporation (“Exact Sciences”). On March 3, Exact Sciences of Madison, Wisconsin, announced the completion of its acquisition of Paradigm and Viomics, cancer diagnostics companies based in Phoenix, Arizona. Paradigm enables Exact Sciences to expand its role in the rapidly evolving field of biomedical diagnostics and personalized medicine, with a specific focus on furthering and diversifying its oncology testing capabilities.

“We are pleased that Paradigm was acquired by industry leading company, Exact Sciences. Our investment in Paradigm helped build momentum in their commercial expansion of the PCDx assay enabling this transaction.” said Mara G. Aspinall, Managing Director of BlueStone Venture Partners. “With this successful acquisition, we are confident that oncologists and their patients will continue to have access to this important diagnostic information about their tumors.”

"The addition of these companies and their talented team members to Exact Sciences is another step forward in extending our leadership in advanced cancer diagnostics," said Kevin Conroy, Chairman and CEO of Exact Sciences.

Paradigm is a Phoenix, Arizona based molecular information company and a pioneer in personalized cancer diagnostics. Paradigm leverages technology, bioinformatics and proprietary sequencing to perform their proprietary PCDx test which identifies the evidence-based treatments that may improve a cancer patient’s progression-free survival. Paradigm delivers results to oncologists in 3-5 business days and is able to provide comprehensive next-generation sequencing (NGS) results including mutational load off of a single slide.

David Mallery, CEO of Paradigm commented “Exact Sciences and Paradigm have teamed up to take on cancer together. By combining our leading portfolio of products, we’re helping people make their most challenging decisions with confidence.”

BlueStone Venture Partners, headquartered in Tucson, Arizona and in Santa Fe, New Mexico, invests in early-stage companies in the Life Sciences field. The Fund primarily focuses on companies in New Mexico, Arizona, Texas and Oklahoma within four key verticals: Medical Devices, Diagnostics, Digital Health and Advanced Materials.

**About BlueStone Venture Partners:** is a life sciences venture fund providing capital and strategic support to innovative technology companies. BlueStone partners with inspired entrepreneurs to help them develop their visions of building industry-leading companies. As BlueStone's principals are leaders within the life sciences, they are able to leverage their deep operational expertise and extensive industry networks to help provide valuable guidance for portfolio companies. Based in Arizona and New Mexico, BlueStone has a geographic preference for companies based in the Southwestern United States. See: [www.bluestonevp.com](http://www.bluestonevp.com) for more information.

**About Exact Sciences:** Founded in 1995, Exact Sciences (Nasdaq "EXAS") is one of the country's premier leaders in molecular diagnostics, relentlessly pursuing smarter solutions to provide the clarity to take life-changing action, earlier. Fueled by the success of Cologuard and Oncotype DX, Exact Sciences is investing in its product pipeline to take on some of the deadliest cancers and improve patient care. Alongside its visionary collaborators and in partnership with communities, Exact Sciences unites the best resources to help advance the fight against cancer. For more information, please visit the company's website at [www.exactsciences.com](http://www.exactsciences.com), follow Exact Sciences on Twitter @ExactSciences, or find Exact Sciences on Facebook.

###

**For more information, please contact:**  
Andrew More, *Director*, BlueStone Venture Partners  
Email: [andrew.more@bluestonevp.com](mailto:andrew.more@bluestonevp.com)